Structure Therapeutics Inc

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.

bluebird bio

Biotech stocks with major catalysts can be powerful capital appreciation vehicles. Bluebird Bio and Structure Therapeutics both have significant events scheduled for next month.

2 Biotech Stocks That Could Soar in December

Announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tolerability profile

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

ImmunityBio

Olink Holding AB

Structure Therapeutics' weight-loss drug candidate is attracting attention over excitement about obesity treatments. ImmunityBio rallied on hopes that its bladder cancer drug will now be better understood by the FDA.

Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Structure Therapeutics (GPCR) rises 9% on encouraging initial data from the early-stage study of its pipeline candidate, GSBR-1290, in healthy overweight or obese individuals.

Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why

Structure Therapeutics' oral small molecule GLP-1, GSBR-1290, has shown promising results in Phase 1b studies, surpassing competitor benchmarks for weight loss. GSBR-1290 demonstrated potential efficacy for weight management and glucose control, making it a viable option for type 2 diabetes patients. Despite a delay in data collection, Structure Therapeutics remains confident in GSBR-1290's potential, and we remain bullish on the potential moving forward.

Structure Therapeutics: Tipping The Scales In Obesity Management

Analysts upgraded their price targets for Structure Therapeutics. The company's obesity therapy can be taken as a once-daily pill.

Why Shares of Structure Therapeutics Are Up Monday

Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced what it called positive results of the Phase 1b multiple ascending dose (MAD) study for its oral GLP-1 receptor agonist, GSBR-1290, a weight loss drug.  Structure Therapeutics said GSBR-1290 demonstrated significant weight loss during the 28-day trial, up to 4.9 kilograms (kg) compared to the baseline, supporting once-daily dosing.

Structure Therapeutics stock soars on positive weight loss data

Structure's weight-loss drug candidate is of the same class as Mounjaro and Wegovy, but while those drugs must be injected, Structure's is taken orally. Structure has also entered into a private stock placement to raise $300 million.

Why Shares of Structure Therapeutics Are Soaring on Friday

Structure's pill is part of the same class of drugs as Novo Nordisk's blockbuster diabetes drug Ozempic and weight loss counterpart Wegovy.

Shares of biotech startup Structure Therapeutics surge more than 30% on promising obesity pill data

Structure said Friday its experimental pill helped patients lose more than 5% of their body weight, and the small biotech stock rocketed.

Structure Soars 32% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment

Shares of Structure Therapeutics soared 60% on Friday after the drug developer's oral obesity treatment succeeded in a small early-stage study.

Structure Therapeutics surges on promising early stage obesity drug data

Structure Therapeutics Inc.'s American depositary receipts GPCR, +4.96% jumped more than 90% premarket on Friday after the company announced positive results from an early-stage trial of a weight-loss treatment and a $300 million private placement. The company's oral GLP-1 receptor agonist, GSBR-1290, resulted in placebo-adjusted weight loss of up to 5% in healthy patients with obesity or overweight after 28 days, the company said in a release.

Structure Therapeutics shares surge after positive results in weight-loss trial, $300 million private placement

$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors

Structure Therapeutics Announces $300 Million Private Placement Equity Financing

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study

Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update

Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. “We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-1290 in individuals living with Type 2 diabetes or obesity toward the end of the year,” said Raymond Stevens, Ph.D.

Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the Biotechnology Innovation Organization (BIO) Board. He recently served as President and Chief Executive Officer of Global Blood Therapeutics until its acquisition by Pfizer in 2022.

Structure Therapeutics Appoints Ted W. Love, M.D.

Earlyworks Co Ltd

Fitell Corp

Inno Holdings Inc

Janover Inc

Keen Vision Acquisition Corp

Neuraxis Inc

ParaZero Technologies Ltd

Pixie Dust Technologies Inc

Surf Air Mobility Inc

Warrantee Inc

A handful of small IPOs and one direct listing closed out the last full week of July. Aviation company Surf Air Mobility completed the first direct listing of 2023, opening 75% below its reference price to begin trading at $5.

U.S. IPO Weekly Recap: July Closes Out With 2023's First Direct Listing And A Wave Of Small IPOs

Cava Group, Inc.

Cadrenal Therapeutics Inc

Genelux Corp

Renaissance IPO ETF

Lichen China Ltd

Lucy Scientific Discovery Inc

Nft Gaming Co Inc/The

Shengfeng Development Ltd

Skyward Specialty Insurance Group Inc

Wang & Lee Group Inc

Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.

IPO Round Up of First Half of 2023

The clinical-stage biotech's lead therapy is designed to treat diabetes and obesity. Structure has enough cash, it said, to fund operations through 2025.

Why Shares of Structure Therapeutics Rose Monday

Structure Therapeutics is working on therapies for diabetes and obesity. Its efforts are still early-stage, but it has plenty of cash to keep going.

This Biotech Is Developing The Next Ozempic. Should You Buy It?

Viking Therapeutics

Novo Nordisk's medicines for obesity and diabetes are spawning many copycats. Viking Therapeutics' stock is soaring thanks to its favorable early results.

Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years

SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego, CA.

Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions

SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company's Founder and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:30 AM ET in New York.

Structure Therapeutics to Present at Jefferies Healthcare Conference

12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results  expected to be announced in latter half of fourth quarter 2023

Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity

Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073 Posters include data across biomarker, translation and clinical studies supporting development of cardiopulmonary programs LTSE-2578 and ANPA-0073

News for Structure Therapeutics Inc Stock (GPCR)